System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 11 citations

PubMed: 39813621 DOI: 10.1182/bloodadvances.2024014105

Current developments in T-cell receptor therapy for acute myeloid leukemia.

Blood Adv 9(12):3069-3089

Authors: Sayali Gore, Emily Blyth, Marie Bleakley, Koon Lee, Kenneth Micklethwaite, Kavitha Gowrishankar

Affiliations

  • School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Children's Cancer Research Unit, The Children's Hospital at Westmead, Sydney, NSW, Australia.
  • School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia.
  • Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
  • Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Department of Pediatrics, University of Washington, Seattle, WA.
  • Children's Cancer Research Unit, The Children's Hospital at Westmead, Sydney, NSW, Australia.

Abstract

T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed toward acute myeloid leukemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T cells targeting single surface antigens have shown remarkable efficacy for B-cell lymphoblastic leukemia, lymphomas, and multiple myeloma. However, AML presents formidable obstacles to the effectiveness of CAR T cells because of the widespread expression of heterogenous leukemia immunophenotypes and surface antigen targets additionally present on normal myeloid cells. TCR therapies are an evolving field of cell therapies that allow targeting intracellular antigenic peptides presented via HLA molecules. The development of TCR therapy for AML is progressing rapidly through preclinical research and successful clinical trials. This review specifically explores the antigens targeted in AML, the diverse methodologies and strategies used in TCR identification, and preclinical TCR T-cell development. The review also discusses innovative molecular designs to improve functional efficacy, mitigate safety concerns, and overcome HLA restrictions. Specific outcomes of early clinical trials targeting important antigens Wilms tumor gene 1, preferentially expressed antigen in melanoma, and minor histocompatibility antigen HA-1 are also highlighted. Ultimately, this review underscores why TCR therapy is poised to become an indispensable component of AML immunotherapy.

MeSH

Genes, Wilms Tumor, Cells, Antigens, Surface, Neoplasms, Leukemia, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Wilms Tumor, Therapeutics, T-Lymphocytes, Hematologic Diseases, Receptors, Antigen, T-Cell